Adipose tissue is a major source of interleukin-1 receptor antagonist - Upregulation in obesity and inflammation

被引:234
作者
Juge-Aubry, CE
Somm, E
Giusti, V
Pernin, A
Chicheportiche, R
Verdumo, C
Rohner-Jeanrenaud, F
Burger, D
Dayer, JM
Meier, CA
机构
[1] Univ Hosp Geneva, Endocrine Unit, Dept Internal Med, Div Endocrinol Diabetes & Nutr, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp, Dept Med, Div Endocrinol Diabetol & Metabol, Lausanne, Switzerland
[3] Univ Hosp Geneva, Dept Internal Med, Div Immunol & Alergy, Hans Wilsdorf Lab, Geneva, NY USA
关键词
D O I
10.2337/diabetes.52.5.1104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The secreted form of the interleukin-1 receptor antagonist (IL-1Ra) is an acute-phase protein intervening in the counterregulation of inflammatory processes. We previously showed that this cytokine antagonist is upregulated in the serum of obese patients, correlating with BMI and insulin resistance. In this study, we examined the expression pattern of IL-1Ra and showed that it is highly expressed not only in liver and spleen, but also in white adipose tissue (WAT), where it is upregulated in obesity. In WAT of obese humans, IL-1Ra was also markedly increased. Moreover, human WAT explants secreted IL-1Ra into the medium, a process that could be stimulated fivefold by interferon-P. Finally, lipopolysaccharide administration induced a longlasting expression of IL-1Ra in mouse WAT, suggesting that adipose tissue is an important source of IL-1Ra mi both obesity and inflammation. In summary, we demonstrated that WAT is one of the most important sources of IL-1Ra quantitatively, suggesting that this tissue could represent a novel target for anti-inflammatory treatment. Moreover, it can be speculated that IL-1Ra, whose production is markedly increased in WAT in obese individuals, contributes further to weight gain because of its endocrine and paracrine effects on the hypothalamus and adipocytes, respectively.
引用
收藏
页码:1104 / 1110
页数:7
相关论文
共 30 条
  • [1] Biological role of interleukin 1 receptor antagonist isoforms
    Arend, WP
    Guthridge, CJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 : 60 - 64
  • [2] BEUTLER BA, 1985, J IMMUNOL, V135, P3969
  • [3] BURGER D, 2000, CYTOKINE REFERENCE, P319
  • [4] Targeting interleukin-1 in the treatment of rheumatoid arthritis
    Dayer, JM
    Bresnihan, B
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (03): : 574 - 578
  • [5] Anti-interleukin-1 therapy in rheumatic diseases
    Dayer, JM
    Feige, U
    Edwards, CK
    Burger, D
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (03) : 170 - 176
  • [6] DELIKAT S, 1993, EXP HEMATOL, V21, P31
  • [7] THE METABOLIC EFFECTS OF INTERLEUKIN-1-BETA ON HUMAN BONE-MARROW ADIPOCYTES
    DELIKAT, SE
    GALVANI, DW
    ZUZEL, M
    [J]. CYTOKINE, 1995, 7 (04) : 338 - 343
  • [8] Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease
    Francis, SE
    Camp, NJ
    Dewberry, RM
    Gunn, J
    Syrris, P
    Carter, ND
    Jeffery, S
    Kaski, JC
    Cumberland, DC
    Duff, GW
    Crossman, DC
    [J]. CIRCULATION, 1999, 99 (07) : 861 - 866
  • [9] INTERLEUKIN-1-ALPHA DECREASES THE SYNTHESIS AND ACTIVITY OF LIPOPROTEIN-LIPASE IN HUMAN ADIPOSE-TISSUE
    FRIED, SK
    APPEL, B
    ZECHNER, R
    [J]. HORMONE AND METABOLIC RESEARCH, 1993, 25 (02) : 129 - 130
  • [10] Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes
    Gabay, C
    Dreyer, MG
    Pellegrinelli, N
    Chicheportiche, R
    Meier, CA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) : 783 - 791